GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.30
−1.52%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.32
From 52W high−33.33%
Volume17.16M
Market cap$835.22M
P/E (TTM)—
P/S (TTM)4.1x
Div yield—
Key dataSep 18, 2026
Open
$1.32
From 52W high
−33.33%
Volume
17.16M
Market cap
$835.22M
ValuationView details →
P/E (Fwd)
77.7x
EV/EBITDA
−15.7x
P/E (TTM)
—
RSI (14)
38.3
MomentumView details →
1D Return
−1.52%
YTD Return
−1.52%
SummaryUpdated Jun 1, 2026
Geron Corporation (NASDAQ:GERN) is a late-stage clinical biopharmaceutical company founded in 1990 and headquartered in Foster City, California. The company went public in 1996 and has focused its efforts on developing therapeutics for blood cancers, specifically myeloid hematologic malignancies. After decades of research and development, Geron achieved a significant milestone in June 2024 with the FDA approval of its lead drug candidate, imetelstat, which is now marketed under the brand name <b>RYTELO</b>. The company has transitioned from a purely clinical-stage entity to a commercial organization with its first approved product generating revenue.
Similar companies
Latest newsMore news →
Geron Corporation granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement to their acceptance of employment, effective September 17, 2026.2d agoKahn Swick & Foti, LLC commenced an investigation into the officers and directors of Geron Corporation.6d ago